The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.

This study is testing a drug called Trop2-ADC (a targeted therapy that delivers chemotherapy directly to cancer cells via a protein called Trop2), used either alone or in combination with immunotherapy, in women with advanced triple-negative breast cancer (TNBC — a type of breast cancer that does not respond to hormone or HER2-targeted treatments). **You may be eligible if...** - You are a woman between 18 and 70 years old - You have metastatic triple-negative breast cancer confirmed by pathology or imaging - You have received no more than two prior lines of treatment for metastatic disease - Your performance status (ability to carry out daily activities) is adequate (ECOG 0–2) - Your expected survival is at least 3 months - You have at least one measurable tumor visible on imaging **You may NOT be eligible if...** - You have had more than two prior lines of therapy for metastatic disease - Your performance status is poor (ECOG 3 or higher) - You have uncontrolled brain metastases - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.